Jasper Therapeutics (NASDAQ:JSPR) Given "Buy" Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Jasper Therapeutics (NASDAQ:JSPR - Free Report) in a report released on Tuesday,Benzinga reports. They currently have a $40.00 price target on the stock.

A number of other equities research analysts have also recently commented on JSPR. UBS Group initiated coverage on shares of Jasper Therapeutics in a research note on Thursday, February 13th. They issued a "buy" rating and a $38.00 price objective on the stock. JMP Securities restated a "market outperform" rating and issued a $70.00 target price on shares of Jasper Therapeutics in a report on Monday, January 6th. Royal Bank of Canada reduced their target price on shares of Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating on the stock in a report on Thursday, January 9th. Finally, BMO Capital Markets initiated coverage on shares of Jasper Therapeutics in a report on Friday, December 6th. They issued an "outperform" rating and a $63.00 target price on the stock. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Jasper Therapeutics has an average rating of "Buy" and an average price target of $62.50.

Jasper Therapeutics Trading Up 2.0 %

Shares of NASDAQ:JSPR traded up $0.11 on Tuesday, reaching $5.49. 153,170 shares of the company were exchanged, compared to its average volume of 267,785. Jasper Therapeutics has a 1-year low of $4.55 and a 1-year high of $31.01. The firm has a market cap of $82.47 million, a price-to-earnings ratio of -1.16 and a beta of 2.23. The company has a 50-day moving average of $6.72 and a 200-day moving average of $15.94.

Remove Ads

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($1.62) EPS for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.35). As a group, analysts forecast that Jasper Therapeutics will post -4.47 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of JSPR. Braidwell LP purchased a new position in shares of Jasper Therapeutics during the 3rd quarter worth about $9,091,000. Boxer Capital Management LLC acquired a new stake in Jasper Therapeutics during the 4th quarter worth approximately $7,483,000. Integral Health Asset Management LLC increased its position in Jasper Therapeutics by 85.7% during the 4th quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company's stock worth $13,897,000 after purchasing an additional 300,000 shares in the last quarter. Ally Bridge Group NY LLC increased its position in Jasper Therapeutics by 82.7% during the 3rd quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company's stock worth $7,514,000 after purchasing an additional 180,852 shares in the last quarter. Finally, Soleus Capital Management L.P. increased its position in Jasper Therapeutics by 11.2% during the 4th quarter. Soleus Capital Management L.P. now owns 1,494,420 shares of the company's stock worth $31,951,000 after purchasing an additional 150,755 shares in the last quarter. 79.85% of the stock is currently owned by hedge funds and other institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.